Results 71 to 80 of about 208,963 (249)

Trend of Visceral Leishmaniasis at Medicine Sans Frontier´s Abdurafi Treatment Center, West Armachiho District, Ethiopia, 2009-2015, a retrospective descriptive analysis

Journal of Interventional Epidemiology and Public Health, 2022
Introduction: Leishmaniasis currently threatens 350 million men, women and children around the world. Visceral leishmaniasis (VL) is a fatal parasitic disease mostly prevalent in low land areas VL typically affects migrant agricultural workers.
Sisay Awoke, Sefonias Getachew, Yimer Seid, Tatek Bogale   +3 more
doaj   +1 more source

The recombinant cysteine proteinase B (CPB) from Leishmania braziliensis and its domains: promising antigens for serodiagnosis of cutaneous and visceral leishmaniasis in dogs. [PDF]

, 2019
Leishmaniasis represents a group of parasitic diseases caused by a protozoan of the genus Leishmania and is widely distributed in tropical and subtropical regions.
Basombrío, Manuel Alberto, Bivona, Augusto Ernesto, Cardoso Landaburu, Alejandro Cesar, Cazorla, Silvia Ines, Cerny, Natacha, Czentner Colomo, Lucas, Estevez, José Octavio, Malchiodi, Emilio Luis, Marco, Jorge Diego, Nevot, María Cecilia, Sanchez Alberti, Andrés   +10 more
core   +1 more source

Effectiveness of dog collars impregnated with 4% deltamethrin in controlling visceral leishmaniasis in Lutzomyia longipalpis (Diptera: Psychodidade: Phlebotominae) populations

Memórias do Instituto Oswaldo Cruz, 2018
BACKGROUND There is little information on the effect of using deltamethrin-impregnated dog collars for the control of canine visceral leishmaniasis. OBJECTIVES The objective of this study was to evaluate the effectiveness of the use of 4% deltamethrin ...
R. A. Silva, A. J. de Andrade, Bruno Beust Quint, Gabriel Elias Salmen Raffoul, G. Werneck, E. F. Rangel, G. Romero   +6 more
semanticscholar   +1 more source

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape

Small, EarlyView.
This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai, Dhwani Rana, Mitali Patel, Neha Bajwa, Rajendra Prasad, Lalitkumar K. Vora   +5 more
wiley   +1 more source

Kidney involvement in leishmaniasis—a review

Brazilian Journal of Infectious Diseases, 2014
Leishmaniasis is an infectious disease caused by protozoa of the genus Leishmania transmitted by insects of the genus Lutzomyia sp. or Phlebotomus sp.
Geraldo Bezerra da Silva Junior, Elvino José Guardão Barros, Elizabeth De Francesco Daher   +2 more
doaj  

Simultaneous Occurrence of Ocular, Disseminated Mucocutaneous, and Multivisceral Involvement of Leishmaniasis

Case Reports in Infectious Diseases, 2014
Leishmaniasis is a tropical infection caused by the protozoan, belonging to the group of Leishmania which causes Old World and New World disease. These are typically divided into cutaneous, mucocutaneous, visceral, viscerotropic, and disseminated disease.
Cyriac Abby Philips, Chetan Ramesh Kalal, K. N. Chandan Kumar, Chhagan Bihari, Shiv Kumar Sarin   +4 more
doaj   +1 more source

Direct-acting antivirals and visceral leishmaniasis: A case report [PDF]

, 2019
Background: Visceral leishmaniasis is a vector-borne parasitic disease caused by protozoa belonging to the genus Leishmania. The clinical presentation of visceral leishmaniasis strictly depends on the host immunocompetency, whereas depressive conditions ...
Cascio, A., Cervo, A., Colomba, C., Di Carlo, P., Firenze, A., Saporito, L., Tolomeo, M., Trizzino, M.   +7 more
core   +1 more source

Leishmaniasis in Patients With Inflammatory Bowel Disease: A National Multicenter Study of GETECCU

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background Leishmaniasis (LI) is a vector‐borne illness caused by a protozoan of the genus Leishmania. Data on the features of LI in patients with inflammatory bowel disease (IBD) are scarce. Aim To describe the characteristics of patients with IBD who present with leishmaniasis, infection outcomes and the risk factors associated with ...
L Madero‐Velázquez, A Mínguez, L Mayorga, JJ Ramírez, N Moreno, C Amorós, MA Nieto, R Mena, JM Benítez, L Gimeno‐Pitarch, N Maroto, C Suria, F Rodríguez‐Moranta, I Ordás, L Ruiz, MA García‐Brenes, A Martín‐Cardona, C Rubín de Célix, K Cárdenas, D Ginard, L Medina, N Pedrero, R Plaza, R Salmoral, TJ Martínez‐Pérez, V Algara, E Merino, Y Zabana, A Gutiérrez, on behalf of Young Group of GETECCU   +29 more
wiley   +1 more source

Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)

Therapeutics and Clinical Risk Management, 2012
Viroj Wiwanitkit1–31Wiwanitkit House, Bang Khae, Bangkok, Thailand; 2Hainan Medical University, Haikou, Hainan, People's Republic of China; 3Joseph Ayo Babalola University, Ikeji-Arakeji, Osun State, NigeriaAbstract: Leishmaniasis is an
Wiwanitkit V
doaj  

Risk factors for visceral leishmaniasis in a new epidemic site in Amhara Region, Ethiopia [PDF]

, 2009
We conducted a case-control study to evaluate risk factors for visceral leishmaniasis during an epidemic in a previously unaffected district of Ethiopia. We also collected blood and bone marrow specimens from dogs in the outbreak villages.
Alvar, Jorge, Aparicio, Pilar, Argaw, Daniel, Bashaye, Seife, Bern, Caryn, Cañavate, Carmen, Chicharro, Carmen, Herrero, Merce, Mulugeta, Abate, Nieto, Javier, Nombela, Nohelly, Vélez, Iván Darío   +11 more
core   +1 more source